Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Lisa Rotellini-Coltvet, Alex Wallace, Gia Saini, Sailendra Naidu, Scott Kriegshauser J, Indravadan Patel, Grace Knuttinen, Sadeer Alzubaidi, JenniferMarino, Rahmi Oklu
This study aims to determine the safety and efficacy of percutaneous transesophageal Gastrostomy (PTEG) in patients with malignant bowel obstructions (MBO). To date, only small case series of PTEG have been published in the U.S. We aim to provide data via a review of PTEG indications, placements, and outcomes in what is the largest case series published in the U.S. A retrospective review of PTEG candidates in Arizona from 2014-2022. A total of 38 cases of PTEG procedures were included in the final data evaluation. The series included 19/38 (50%) male patients and 19/38 (50%). Three (8%) PTEG placements were performed without the use of anesthesia while the remainder (92%) were performed on patients under anesthesia. Clinical indication, method of placement, clinical outcome, mortality following placement and efficacy were evaluated. All PTEG placements were on the left side. All patients with successful PTEG placement experienced improved clinical symptoms. Technical success was achieved in 35/38 (92%) of patients. Overall, this large case series has proven that PTEG is a viable and durable option for patients with relative or absolute contraindications to traditional percutaneous gastrostomy tube placement for venting for MBO, proving itself to be an essential tool for oncology patients.